This site is intended for healthcare professionals

Eton Pharmaceuticals sells its neurology portfolio to Azurity Pharmaceuticals, namely ET 101, ET 104 and ET 105 which are all under FDA review.

Read time: 1 mins
Last updated:28th Jun 2021
Published:9th Feb 2021
Condition: Epilepsy
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest